The precise role of a-actinin-4 encoding gene (ACTN4) is not very well understood. It has been reported to elicit tumor suppressor activity and to regulate cellular motility. To further assess the function of human ACTN4, we studied a lung carcinoma cell line expressing a mutated aactinin-4, which is recognized as a tumor antigen by autologous CD8 þ cytotoxic T lymphocytes (CTL). Confocal immunofluorescence microscopy indicated that, while wild-type (WT) a-actinin-4 stains into actin cytoskeleton and cell surface ruffles, the mutated protein is only dispersed in the cytoplasm of the lung carcinoma cells. This loss of association with the cell surface did not appear to correlate with a decrease in in vitro a-actinin-4 crosslinking to filamentous (F)-actin. Interestingly, experiments using cell lines stably expressing ACTN4 demonstrated that as opposed to WT gene, mutant ACTN4 was unable to inhibit tumor cell growth in vitro and in vivo. Moreover, the expression of mutant a-actinin-4 resulted in the loss of tumor cell capacity to migrate. The identification of an inactivating mutation in ACTN4 emphasizes its role as a tumor suppressor gene and underlines the involvement of cytoskeleton alteration in tumor development and metastasis.
Introduction a-Actinins are proteins of approximately 100 kDa encoded by members of the spectrin gene superfamily. They include an amino-terminal actin-binding domain, a central rod composed of four spectrin-like repeats (Davison and Critchley, 1988) , and a calmodulin-like domain at the carboxy-terminus. In vivo, a-actinins are organized as antiparallel homodimers and form a rodshaped complex with an actin-binding domain at each end (Djinovic-Carugo et al., 1999) . So far, four human a-actinin genes (ACTN) have been described. The ACTN2 and ACTN3 are expressed in cardiac and/or skeletal muscles (Beggs et al., 1992) . The ACTN1 gene is expressed ubiquitously (Millake et al., 1989) , and its product was described to play a major role in stabilizing cell adhesion and regulating cell shape and cell motility (Otey et al., 1993) . a-Actinin-1 is involved in the organization of the cortical cytoskeleton adjacent to membrane-associated structures by crosslinking actin filaments and interacting with numerous cytoskeletaland membrane-associated proteins (Djinovic-Carugo et al., 1999) . It may link the actin cytoskeleton to the membrane either directly, via interactions with transmembrane receptors such as integrins, ICAMs and Lselectin (Carpen et al., 1992) , or indirectly, via cytoskeletal proteins such as vinculin (Wachsstock et al., 1987) . The ACTN4 gene was cloned recently by screening a cDNA expression library with an anti-a-actinin monoclonal antibody (mAb), produced against a human lung cancer cell line, whose pattern of staining differed from that of anti-a-actinin-1 Ab (Honda et al., 1998) . Human a-actinin-4 displays 87% identity with a-actinin-1, and it is also expressed ubiquitously, but its precise role is still not very well understood. It has been reported to regulate actin cytoskeleton, enhance cell motility (Honda et al., 1998) and to elicit tumor suppressor activity (Nikolopoulos et al., 2000) .
Cell adhesion plays a critical role in malignant transformation through dynamic interactions between the extracellular matrix (ECM) and the actin cytoskeleton (Hynes, 1992) . Early studies of transformed cells showed a direct association between disorganization of the cytoskeleton and tumorigenicity or invasive capacity (Ben-Ze'ev, 1997) . It has been shown that the expression of actin-associated proteins such as a-actinin-1 was decreased in cancer cells and that increased expression after cell transfection with cDNA encoding such proteins could reduce or abrogate metastatic potential (Gluck et al., 1993; Janmey and Chaponnier, 1995) . Along the same line, human ACTN4 gene was recently reported to suppress tumorigenicity of human neuroblastoma cells, suggesting its possible role as a tumor suppressor gene. In this regard, while a high level of ACTN4 expression was found in nontumorigenic neuroblastoma cell variants, little or no expression was observed in malignant neuroblasts (Nikolopoulos et al., 2000) .
We have recently identified a human lung carcinoma cell line expressing a mutated a-actinin-4 protein, which is recognized as a tumor antigen by autologous CD8 þ cytotoxic T lymphocytes (CTL) derived from tumor infiltrating lymphocytes (TIL; Echchakir et al., 2002 Echchakir et al., , 2001 ). This point mutation (K122N) is located upstream of the actin-binding domain. In the present report, we investigated the influence of the identified mutation on a-actinin-4 protein expression and cytoskeleton organization, and examined its effect on ACTN4 tumor suppressor activity and cell motility. The present study provides evidence indicating that the identified mutation is directly associated with the loss of a-actinin-4 antiproliferative function and further supports the classification of ACTN4 as a tumor suppressor gene.
Results
ACTN4 point mutation disrupts a-actinin-4 association with actin cytoskeleton and interferes with cell surface ruffles formation
We have previously identified a mutated ACTN4 gene, which encoded a tumor antigen recognized on a human lung carcinoma cell line, IGR-Heu, by autologous HLA-A2-restricted CTL (Echchakir et al., 2001 . The point mutation, which is essential for T-cell recognition, resulted in a substitution of a Lys to an Asn, localized in close proximity of the actin-binding domain, in a highly conserved region of the four human a-actinins and of the a-actinins of several other species ( Figure 1a ). This mutation does not affect the Figure 1 (a) a-Actinin sequences alignment. The alignment of a-actinin protein sequences includes all four human proteins and aactinins from other species with available sequences. The mutated a-actinin-4, expressed by the IGR-Heu lung carcinoma cell line, harboring a Lys4Asn substitution at position 122 (bold letter) of the protein is included. The epitope recognized by the autologous CTL clone is underlined and the actin-binding site is shown in a lined box. (b) Confocal immunofluorescence microscopy showing a-actinin-4 and actin cytoskeleton. Double fluorescence analysis of a-actinin-4, labeled by a rabbit polyclonal Ab detected with an FITC-conjugated goat anti-rabbit Ab (green) and actin filaments visualized with Texas red-conjugated phalloı¨din (red) is shown. a-Actinin-4 colocalizes specifically with actin stress fibers (yellow) in IGR-Pub and ADC-Coco (arrows), and is expressed exclusively in the cytoplasm of IGR-Heu cells (arrowhead). For each cell line, the lower panel corresponds to a higher magnification of the upper one a-actinin-4 expression level as indicated by RT-PCR and Western blot analyses (data not shown). To determine whether the identified mutation affects a-actinin-4 association with actin cytoskeleton, we examined its cell surface and cytoplasmic expression in IGR-Heu and a panel of tumor cell lines harboring the wild-type (WT) gene. Confocal immunofluorescence microscopy, performed with anti-a-actinin-4-specific polyclonal Ab (green) combined with Texas red-phalloı¨-din (red), indicated that all the tested lung tumor cell lines expressing the WT gene display an intense a-actinin-4 staining and colocalization with actin (yellow) into the cell surface, the active membrane ruffles (protrusions) and the cytoplasm (Figure 1b) . No a-actinin-4 nuclear distribution was observed in all the cell lines tested (Figure 1b and data not shown). In contrast, IGR-Heu cells display a-actinin-4 staining into the cytoplasm exclusively and lack cell surface ruffling ( Figure 1b) . The absence of a-actinin-4 colocalization with actin suggests that the point mutation resulted in the loss of a-actinin-4 ability to associate with actin cytoskeleton.
To determine whether the defect in mutant a-actinin-4 association with actin cytoskeleton correlates with an alteration in its capacity to crosslink filamentous (F)-actin, we investigated its actin-binding activity in vitro. For this purpose, full-length WT and mutant cDNA were generated using the previously described incomplete 57 cDNA (Echchakir et al., 2001) . Radiolabeled in vitro translated WT and mutated a-actinin-4 were incubated with F-actin under polymerizing conditions. A higher percentage of the mutant a-actinin-4 cosedimented with actin filaments under high-speed centrifugation compared with the WT protein (Figure 2a and b) . In control samples run in parallel, no detectable mutant or WT labeled a-actinin-4 sedimented under 100 000 g centrifugation in the absence of actin, indicating that the mutant protein was not aggregating (Figure 2b ). Furthermore, in vitro translated luciferase did not cosediment with actin confirming binding specificity (Figure 2a ). These results suggest that the mutation identified in the lung carcinoma may enhance in vitro binding of a-actinin-4 to F-actin.
Loss of tumor growth inhibitory potential of mutated ACTN4
It has been previously reported that ACTN4 may function as a tumor suppressor gene (Nikolopoulos et al., 2000) . However, no inactivating mutation, a prerequisite for its formal designation as a tumor suppressor gene (Haber and Harlow, 1997) , has so far been identified. Therefore, we compared the effect of the WT and mutated ACTN4 cDNA on tumor cell growth. For this purpose, we used the highly tumorigenic BE(2)C neuroblastoma cell line, previously described to express a very low basal level of a-actinin-4 protein (Nikolopoulos et al., 2000) . This cell line was transfected Figure 2 Actin-binding experiments. WT and mutated a-actinin-4 were synthesized with a coupled transcription/translation TnT kit. The indicated amounts of the TnT reactions were incubated with or without 5 mM F-actin. After centrifugation, the pellets were resuspended, denaturated and each fraction were submitted to SDS-PAGE. (a) Gel showing actin cosedimentation experiments. Supernatant (S) and resuspended pellet (P) of sedimented samples containing F-actin and WT-or mutant a-actinin-4-containing extracts were loaded on the gel. In vitro translated luciferase was used as a control for binding specificity. (b) Graphical representation of the results of cosedimentation experiments conducted in the presence of different amounts of in vitro translated WT or mutant a-actinin-4 and pure F-actin. The fraction of a-actinin-4 cosedimenting with actin was determined by Phosphorimager quantification. Data correspond to percentage of sedimenting fraction Figure 3 a-actinin-4 expression in BE(2)C-derived cell lines. (a) ACTN4 cDNA expression in parental BE(2)C, BE(2)C transfected with empty pcDNA3.1 (pcDNA3.1) and BE(2)C transfected with WT (clone G20) or mutated ACTN4 cDNA (clone A8) was determined by RT-PCR. cDNA overexpression is observed in both G20 and A8, as opposed to BE(2)C, and BE(2)C transfected with pcDNA3.1, which express almost no a-actinin-4. (b) Confocal immunofluorescence microscopy analysis of a-actinin-4 labeled by a rabbit polyclonal Ab, detected with an FITC-conjugated goat anti-rabbit Ab (green), and actin filaments visualized with Texas redconjugated phalloı¨din (red) in parental BE(2)C, BE(2)C transfected with empty pcDNA3.1 (pcDNA3.1), BE(2)C transfected with WT ACTN4 cDNA (clone G20) and BE(2)C transfected with mutated ACTN4 cDNA (clone A8). Parental and pcDNA3.1-transfected BE(2)C cells express a very low level of a-actinin-4. WT a-actinin-4 colocalizes with actin stress fibers (yellow) and induces cell surface ruffles in G20 clone (arrow). In contrast, although a high expression level of the mutated a-actinin-4 induced its presence at the cell surface, the protein is not associated with membrane ruffling formation in mutant ACTN4-transfected A8 clone (arrowhead). (c) Phase-contrast photomicrograph of WT (G20) and mutant (A8) ACTN4-transfected clones compared to parental BE(2)C and BE(2)C transfected with empty pcDNA3.1 controls ( Â 20 magnification). While WT ACTN4 cDNA leads to dramatic morphological changes, cells stably transfected with mutated ACTN4 cDNA showed a morphology comparable to the parental BE(2)C or BE(2)C transfected with empty pcDNA3.1
Role of ACTN4 in tumorigenicity and cell motility J Menez et al with full-length WT or mutant ACTN4 cDNA and several stable transfectants were isolated. Two clones stably transfected with WT cDNA (designated G20 and G24) and two clones stably transfected with mutant cDNA (designated A4 and A8) were selected on the basis of their resistance to neomycin and a-actinin-4 expression. RT-PCR (Figure 3a ), Western blot (data not shown) and confocal microscopy (Figure 3b ) analyses demonstrated a high increase of a-actinin-4 mRNA and protein expression in all selected clones. It is worth noting that, while WT a-actinin-4 is expressed into transfected BE(2)C cell surface and associated with cell surface ruffles formation, the mutated protein failed to induce membrane ruffling, although its high expression level induced its expression in the cytoplasm and its presence at the cell surface ( Figure 3b) . Furthermore, morphological studies indicated that tumor cells transfected with WT cDNA (G20) exhibit dramatic morphological changes as compared to BE(2)C parental cells and to mutant ACTN4 transfectants (A8). Indeed, while the latter cells were small, rounded and grew in compact aggregates, as the parental BE(2)C cells and IGR-Heu lung tumor cell line (data not shown), WT ACTN4 transfectants were large, flattened and grew separately (Figure 3c ). Moreover, variation of the proliferation capacity of the latter cells was observed and the growth rate of the majority of the cells was dramatically reduced and even a growth arrest was observed after few passages as compared to mutant ACTN4 transfectants, the parental BE(2)C or empty vector-transfected controls (data not shown).
We then investigated the tumorigenicity of WT and mutated ACTN4 transfectants in vitro and in vivo. WT ACTN4-transfected BE(2)C cells displaying an intermediate grow rate were used for these experiments. Analysis of colony-forming efficiency in soft agar indicated that WT ACTN4-transfected cells are much less malignant than mutant ACTN4 transfectants, empty vector-transfected controls or parental cells (Figure 4a ). Indeed, BE(2)C transfected with WT ACTN4 (G20) show five-to 10-fold lower colonyforming efficiencies than BE(2)C transfected with mutated ACTN4 (A8). In further experiments, WT and mutated ACTN4 transfectants were tested for their malignant potential in athymic nude mice. For this purpose, 10 7 cells per mouse of BE(2)C, pcDNA3.1-transfected BE(2)C, WT or mutant ACTN4-transfected BE(2)C were injected subcutaneously and tumor growth was then measured. In two independent experiments (a total of 10 mice per cell line for each experiment), mutant ACTN4-transfected BE(2)C and both control untransfected and empty vector-transfected cells were tumorigenic in at least half of the engrafted animals. In contrast, only two mice out of the 10 inoculated with WT ACTN4 stable transfectants (G20) lately developed tumors during the 45-day observation period (Figure 4b ). In addition, tumor growth in these latter two mice was considerably reduced as compared to mutant ACTN4-transfected cells (A8), untransfected or empty vector-transfected BE(2)-C controls (Figure 4c ). These results emphasize that the point mutation in ACTN4 abrogates its tumor suppressor function.
Mutated ACTN4 affects tumor cell migration
It has been reported that ruffles are required for directed cell migration (Araki et al., 2000) , and active membrane ruffling of cancer cells is considered to be a parameter of tumor cell invasion and metastasis (Jiang, 1995) . However, a more recent report indicates that tumor cells can move without filopodial extensions (Friedl and Wolf, 2003) . To determine whether the mutant ACTN4 gene affects tumor cell migration, we analysed in vitro the migratory potential of IGR-Heu and a panel of lung tumor cell lines harboring the WT gene, using polycarbonate filters. While all the latter tumor cells tested (two are shown) are able to migrate, the IGR-Heu cell line displays no capacity to migrate (Figure 5a and c, left  panel) . This migration deficiency correlates with lack of ruffles formation at the IGR-Heu cell surface.
To further assess the inhibitory effect of mutant ACTN4 on the migratory potential of tumor cells, we investigated the capacity of mutant ACTN4 BE(2)C transfectants (A8) to migrate in vitro. BE(2)C and BE(2)C transfected with pCDNA3.1 empty vector were used as controls. The results indicate that mutated ACTN4-transfected BE(2)C cells display a reduced capacity to migrate as compared to parental BE(2)C cell line or pcDNA3.1-transfected cells (Figure 5b and c, right panel). The migration of BE(2)C parental cells may result from an increase in the fluidity of the cytoskeleton associated with a decrease in cell adhesion in the absence of a-actinin-4 expression. These results emphasize that a-actinin-4 regulates cell motility (Honda et al., 1998; Kos et al., 2003) , and further suggest that at least the mutant form of the gene affects cell migration.
Discussion a-Actinins crosslink F-actin to form actin filament stress fibers and mediate plasma membrane/F-actin interactions via several proteins including talin, vinculin and integrin (Wachsstock et al., 1987; Burridge et al., 1990 ; Otey et al., 1990; Miyamoto et al., 1995; Ben-Ze'ev, 1997). The first described nonmuscle a-actinin, namely actinin-1, is primarily located in focal adhesion structures and participates in cadherin-mediated cell-cell adhesion via a-catenin at adherens junctions (Horwitz et al., 1986; Geiger et al., 1992; Fujimori and Takeichi, 1993; Otey et al., 1993; Knudsen et al., 1995) . It has been reported that actinin-1 encoding gene (ACTN1) is able to suppress tumorigenicity and to regulate cell shape and cell motility Gluck et al., 1993; Ben-Ze'ev et al., 1994; Gluck and Ben-Ze'ev, 1994; Knudsen et al., 1995) . Regarding the more recently identified nonmuscle a-actinin, a-actinin-4 (Honda et al., 1998), much less is known about its role in cytoskeletal organization and its precise biological function. It has been reported that the a-actinin-4-encoding gene (ACTN4) may also suppress tumorigenicity (Nikolopoulos et al., 2000) , but in contrast to ACTN1 it may enhance cell motility (Honda et al., 1998) . We have previously identified a mutated ACTN4 gene, which encodes a tumor epitope recognized by autologous CD8
þ CTL in HLA-A2-restricted context (Echchakir et al., 2001) . Point mutations in genes encoding proteins implicated in actin cytoskeleton and þ or CD4 þ T lymphocytes. Among these genes, a point mutation in the b-catenin encoding gene, the product of which also binds actin, was shown to encode an antigen specifically recognized on a melanoma by CD8 þ CTL (Robbins et al., 1996) . More recently, a mutated fibronectin, implicated in ECM formation, has been identified as a tumor antigen recognized by CD4 þ T cells (Wang et al., 2002) . The biological function of the mutated Ag identified by tumor-reactive CD4 þ and CD8 þ T cells suggests that these gene products are not only targets of antitumor immune response but also contribute to tumor development and metastasis. Such Ag would serve as ideal targets for human cancer immunotherapy (Beck-Engeser et al., 2001) . The identification of a mutated aactinin-4 as a tumor Ag may allow to improve our understanding of the biological function of ACTN4 gene and the mechanisms by which it may participate in tumorigenesis and metastasis.
As opposed to a-actinin-1, which was described to be concentrated in actin stress fiber ends in plasma membrane adherens junctions and focal adhesion Knudsen et al., 1995; Miyamoto et al., 1995; Honda et al., 1998) , a-actinin-4 colocalizes with actin and appears to crosslink stress fibers, suggesting differential protein functions (Honda et al., 1998) . In the present report, we show that unlike WT aactinin-4, which localizes to the cell edge in membrane ruffles and in the cytoplasm where cells were sharply extended (Honda et al., 1998; Araki et al., 2000; Gonzalez et al., 2001) , mutated a-actinin-4 exclusively accumulates in the cytoplasm of the lung carcinoma cells. In addition, cancer cells harboring the mutant protein fail to display cell surface ruffling. This result suggests that the mutated a-actinin-4 has lost its capacity to associate with the dynamic actin cytoskeleton in motile regions of the cell. Similarly, it has been reported that actin stress fibers were poorly developed in different human cancer cell lines and that a-actinin-4 was diffusely dispersed in the cytoplasm (Honda et al., 1998) . In addition, a nuclear distribution of a-actinin-4 was observed in various tumor cells (Honda et al., 1998) , and seemed to correlate with the expression of a truncated form of the protein (Gonzalez et al., 2001 ). Therefore, a-actinin-4 expression and localization often appear to be altered in human tumor cells.
The loss of mutant a-actinin-4 staining into the cell surface of IGR-Heu lung carcinoma cells did not appear to be associated with a defect in its ability to bind to Factin. Indeed, in vitro binding assays indicated that mutant a-actinin-4 binds at least as efficiently to F-actin as the WT protein. These results suggest that the association of a-actinin-4 with some other cytoskeletal proteins is altered by the mutation. Alternatively, and most likely, the in vitro binding assay may not reflect physiological conditions. An increase in mutant aactinin-4 in vitro binding to F-actin has been previously reported in familial focal segmental glomerulosclerosis (Kaplan et al., 2000) . Indeed, three mutations in ACTN4 gene located at positions 228, 232 and 235, which affect the region between the actin-binding domain and the first rod domain of the protein, lead to an increase in aactinin-4 in vitro binding to F-actin. Therefore, alteration in the actin cytoskeleton may not only be implicated in malignant transformation but also in the pathophysiology of kidney disease.
Previous studies have shown that proteins involved in cytoskeletal organization and cell adhesion are frequently downregulated or mutated in tumors and transformed cell lines (Ben-Ze'ev, 1997), and that their reexpression via transfection reduces malignant potential Gluck et al., 1993; Boyd et al., 1995; Janmey and Chaponnier, 1995) . Interestingly, a notion has emerged that some cell adhesion molecules, known to be associated with the cytoskeletal network, may work as a tumor suppressor (Tsukita et al., 1993) . Among these proteins, the actinassociated proteins such as a-actinin-1 (Gluck et al., 1993; Gluck and Ben-Ze'ev, 1994 ), a-actinin-4 (Nikolopoulos et al., 2000), vinculin , tropomyosins 1 and 2 (Prasad et al., 1993; Gimona et al., 1996) as well as the transmembrane receptor proteins and their substrates, such as a2b1 integrin receptor (Zutter et al., 1995) , E-cadherin (Vleminckx et al., 1991) and a-catenin, a subunit in the cadherin/catenin complex (Bullions et al., 1997) and ECM components such as fibronectin (Akamatsu et al., 1996) were previously reported to exhibit tumor suppressor function. The present study indicates that as opposed to WT ACTN4, which is able to downmodulate the malignant potential of the highly malignant BE(2)C neuroblastoma cells (Nikolopoulos et al., 2000) , the mutated gene had no effect on tumorigenicity, as measured by colony-forming efficiency in soft agar and tumor formation in nude mice. Our results suggest that, rather than being a consequence of cell transformation, the mutation in ACTN4 may represent a causative event contributing to malignant transformation. Indeed, efforts to isolate stable IGR-Heu transfectants overexpressing WT a-actinin-4 were unsuccessful and transfected tumor cells either ceased to proliferate or exhibited a truncated ACTN4 cDNA (data not shown). These results further support the observation that the expression of WT ACTN4 inhibits cell growth. The identification, for the first time, of a point mutation that abolishes the tumor suppressor function of ACTN4 further supports its designation as a canonical tumor suppressor gene.
a-Actinin-4 has been described as a new marker of normal (Araki et al., 2000) and tumor (Honda et al., 1998) cell motility, and was associated with the metastatic potential of tumor cells (Honda et al., 1998) . IGR-Heu lung carcinoma cells, harboring mutated a-actinin-4, exhibit a defect in migratory capacity as shown in vitro. These data, as well as studies performed with mutant ACTN4-transfected BE(2)C cells, support a potential role of WT a-actinin-4 in enhancing cell motility (Honda et al., 1998) and suggest that the point mutation may alter this function. However, preliminary motility assays performed with WT ACTN4-transfected BE(2)C cells trend toward cell motility inhibition similar to that observed with the mutant gene (data not shown). This result supports recent studies performed in a-actinin-4-deficient mice, suggesting an inhibitory role of ACTN4 on cell movement. According to this alternative hypothesis, the identified mutation may not affect the function of aactinin-4 related in cell motility and exclusively alter its antiproliferative/tumor suppressor role. The finding that mutant a-actinin-4 confers tumorigenicity but inhibits cell motility suggests that no correlation between tumor cell proliferation and invasiveness may exist in some cancers. Mutated a-actinin-4 may lead to an increased cell adhesion and therefore decreased motility. The correlation between adhesion and motility has been previously documented . However, mutations affecting other genes implicated in cell motility regulation may not be excluded. Signals for growth control need to be more clearly elucidated, but appear to be transmitted through integrins and require an 'organized' association of the microfilaments with adhesion sites. The generation of ACTN4-deficient mice (Kos et al., 2003) may allow further investigation of the regulatory function of a-actinin-4 in the control of cell growth and motility.
Materials and methods

Tumor cell lines and culture conditions
The NSCLC tumor cell line, IGR-Heu, was derived from a large cell carcinoma (LCC) of the lung as previously described (Asselin-Paturel et al., 1998) , and cultured in DMEM/F12 medium containing 10% heat-inactivated FCS, 1% Ultroser G (Gibco BRL, Life Technologies, Cergy Pontoise, France) and 1% penicillin-streptomycin, at 371C in a humidified atmosphere with 5% CO 2 . The ADC-Coco tumor cell line was established from an adenocarcinoma (ADC) of the lung. The IGR-Pub (ADC) lung tumor cell line was derived as previously described , and maintained in the same culture conditions. The BE(2)C neuroblastoma cell line was purchased from ATCC (American Type Culture Collection, Manassas, VA, USA) and cultured in DMEM/F12 medium supplemented with 10% FCS (Seromed, Berlin, Germany).
Cloning of full-length ACTN4 cDNA and cell transfection
Total RNA was extracted from IGR-Heu tumor cell line using Trizol Reagent (Invitrogen, Groningen, The Netherlands). Total RNA (5 mg) was reverse transcribed to cDNA using a cDNA Cycle Kit (Invitrogen) in a total volume of 20 ml. A total of 2 ml of cDNA was amplified by PCR including 35 cycles at 551C as hybridization temperature using Taq DNA polymerase (New England Biolabs, Beverly, USA). The fulllength mutated ACTN4 cDNA was cloned using the previously described 3161 bp long cDNA clone 57 (cloned in pcDNA3.1), which was lengthened by 104 bp at the 5 0 end by replacing the HindIII-BstEII fragment upstream of the mutation by a PCR fragment, generated using forward primer 5 0 -GGCCCAA GCTTCGGTGGGCGAGCGAGA-3 0 (including HindIII site) and reverse primer 5 0 -GAGCCCTTCCTTGGCCGA-3 0 , digested by the same restriction enzymes. The full-length WT ACTN4 was generated by replacing the HindIII-Bsu36I fragment including the mutation, by a PCR fragment amplified from a WT cDNA using the same primer pairs and cut by the latter restriction enzymes. Both constructions were sequenced using dideoxy chain method in an ABI 310 automated DNA sequencer (Perkin-Elmer Applied Biosystems, Warrington, Great Britain) and transfected into the BE(2)C cell line using the Superfect reagent kit (Qiagen, Courtaboeuf, France), according to the manufacturer's instructions. Stable transfectants were selected by the addition of G418 (500 mg/ml, Invitrogen) for 5 weeks and then cloned by limiting dilution. Several clones were obtained; four of them were selected for their resistance to G418 and the stable expression of a-actinin-4 as examined by Western blot analysis. They were maintained for several weeks in the same culture medium complemented with 500 mg/ml of G418.
Confocal immunofluorescence microscopy
Rabbit polyclonal antisera specific for human a-actinin-4 was generated using NQSYQYGPSSAGNGAGC polypeptide, corresponding to the NH 2 -terminal sequence of the protein, conjugated with keyhole limpet hemocyanin (KLH) via the added carboxy-terminal cysteine, as described (Kaplan et al., 2000) . In total, 3 Â 10 5 cells were cultured on coverslips in sixwell plates (Nunc, Roskilde, Denmark). After an overnight culture, cells were fixed with 4% paraformaldehyde, 0.025% glutaraldehyde in PBS and made permeable with 0.1% Triton X-100 in PBS. After two saturation steps with PBS 50 mM NH 4 Cl and PBS 1% BSA, cells were incubated with anti-aactinin-4 Ab. a-Actinin-4 labeling was then detected with an FITC-conjugated goat anti-rabbit Ab, and actin filaments were visualized with Texas Red-conjugated Phalloı¨din (Sigma, St Quentin Fallavier, France). Cells were then examined with a Zeiss confocal microscope (LSM510, Zeiss, Le Pecq, France).
Actin-binding experiments
Full-length mutated or WT ACTN4 cDNA, previously cloned in pcDNA3.1 vector, were in vitro translated in a 50 ml reaction using a TnT coupled Reticulocyte Lysate kit (Promega, Charbonnie`res, France), in the presence of 35 S-methionin. Electrophoresis on a 10% acrylamide gel confirmed the presence of the expected B100 and B60 kDa proteins, corresponding, respectively, to a-actinin-4 (examined by Western blotting) and control luciferase. We then incubated the labeled in vitro translated products (0, 0.5, 1, 2 and 4 ml) with purified monomeric F-actin (5 mM final), in 40 ml of F buffer (5 mM Tris, pH 7.5, 1 mM dithiothreitol, 0.1 mM CaCl 2 , 1 mM MgCl 2 , 0.1 M KCl). Actin was allowed to polymerize for 20 min at RT, and the reactions were centrifuged at 100 000 g for 45 min at 181C. We then removed the supernatant and resuspended the pellet in the initial 40 ml volume of SDS gel loading buffer. Supernatants and pellets were submitted to SDS-PAGE followed by autoradiography (phosphoImager, FLA-300, Fujifilm, Saint Quentin en Yvelines, France) to quantitate the 100 kDa polypeptide. The amount of sedimented a-actinin-4 was then determined as a percentage of the total protein detected in the pellet plus the supernatant.
Tumorigenicity assays
Assays of colony formation were performed in six-well plates as described (Spengler et al., 1997) . For each plate, three wells were first precoated with a complete medium containing 0.5% agar. In total, 10 4 cells were then seeded in a complete medium supplemented with G418 and 0.25% agar. The same number of cells was also seeded in a complete medium supplemented with G418 in the absence of agar in the three empty wells. At day 7, the number of colonies formed in soft agar was determined and the total number of cells grown in the monolayer was obtained after trypsin treatment and counting. The percentage of cells that formed colonies corresponds to the colony-forming efficiency.
For the determination of in vivo tumor formation, 10 7 cells were injected subcutaneously in 6-to 8-week-old athymic nude mice (10 mice/cell line). Mice were then examined twice a week for 6-7 weeks, tumor size was measured and the volume was calculated according to the following formula: volume ¼ 0.5 Â longest diameter Â (shortest diameter) 2 .
Migration assay
The transwellt system (Costar, Cambridge, UK) was used to evaluate the tumor cell migration. In total, 2 Â 10 5 tumor cells were resuspended in 200 ml of complete medium, and added to the upper compartment of the chamber. A volume of 600 ml of complete medium containing 30% fetal calf serum was previously added to the lower compartment. The chambers were then incubated 24 h at 371C, in 5% CO 2 . After incubation, cells in the lower chamber were counted after trypsin treatment and those that crossed but attached to the lower side of the chamber membrane were stained with Draq5t (Alexis Biochemicals, Lausen, Switzerland), examined and counted from four different fields under fluorescence microscope. The results were expressed as the mean of the number of migrating cells per well.
Abbreviations CTL, cytotoxic T lymphocytes; WT, wild-type; Mut, mutant; F-actin, filamentous-actin; mAb, monoclonal antibodies; ECM, extracellular matrix.
